Fluciclovine PET/CT in Multiple Myeloma Patients
NCT03966443 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10
Last updated 2019-05-30
Summary
Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients
Conditions
- Myeloma, Multiple
- PET-CT
Sponsors & Collaborators
-
Oslo University Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-03-01
- Primary Completion
- 2020-01-31
- Completion
- 2029-01-31
Countries
- Norway
Study Locations
More Related Trials
-
Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.
NCT00200668 ·Status: TERMINATED ·Phase: NA
-
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
NCT04410133 ·Status: COMPLETED ·Phase: PHASE3
-
Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma
NCT03188354 ·Status: COMPLETED ·Phase: NA
-
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
NCT03276676 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Fluciclovine (18F) Imaging of Breast Cancer
NCT03036943 ·Status: COMPLETED ·Phase: NA
-
Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma
NCT04114370 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)
NCT04349358 ·Status: RECRUITING ·Phase: NA
-
Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma
NCT03496844 ·Status: COMPLETED ·Phase: NA
-
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
NCT00935090 ·Status: RECRUITING
-
A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma
NCT05448404 ·Status: UNKNOWN ·Phase: NA
-
Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases
NCT04111588 ·Status: RECRUITING
-
Diagnostic Imaging of Myeloma Bone Lesions
NCT03147326 ·Status: COMPLETED ·Phase: NA
-
F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML)
NCT01592266 ·Status: UNKNOWN
-
Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast
NCT01659645 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
18F-FLUC PET/MR in Patients With Brain Mets
NCT06159335 ·Status: RECRUITING ·Phase: PHASE3
-
18F-Fluciclovine PET and Multiparametric MR Imaging
NCT03925675 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM
NCT00943462 ·Status: WITHDRAWN
-
Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT
NCT02103530 ·Status: COMPLETED ·Phase: NA
-
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
NCT04410367 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy
NCT02193672 ·Status: WITHDRAWN ·Phase: PHASE1
-
18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis
NCT03930173 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
NCT06055790 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
NCT03832127 ·Status: RECRUITING ·Phase: PHASE1
-
Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT
NCT04271436 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies
NCT02042924 ·Status: TERMINATED ·Phase: NA